A Retrospective Study of Treatment of Squamous Cell Carcinoma In situ by Övermark, Meri et al.
Acta Derm Venereol 96
CLINICAL REPORT
Acta Derm Venereol 2016; 96: 64–67
© 2016 The Authors. doi: 10.2340/00015555-2175
Journal Compilation © 2016 Acta Dermato-Venereologica. ISSN 0001-5555
Squamous cell carcinoma in situ is an intra-epidermal 
malignancy of the skin with potential to progress to in-
vasive carcinoma. Commonly used treatments are surgi-
cal excision, cryotherapy, photodynamic therapy, laser 
ablation, curettage with cautery, radiotherapy, topical 
5-fluorouracil, and topical imiquimod. The efficacies of 
these different treatment modalities are compared in 
this retrospective study of 239 patients with squamous 
cell carcinoma in situ diagnosed and treated at our hos-
pital during a period of 1 year. A total of 263 histolo-
gically confirmed in situ lesions were followed up for 
approximately 8 years. The overall recurrence rate was 
6.5%. Surgical excision had the lowest recurrence rate, 
at 0.8%. Recurrence rates with the less-invasive treat-
ment modalities were markedly higher; cryotherapy 
4.7% and photodynamic therapy 18%. Of all recurren-
ces, 65% were carcinoma in situ and 35% squamous cell 
carcinomas. Twenty-three patients had actinic keratosis 
in the area treated, but these were not counted as re-
currences. In conclusion, excisional surgery is the gold 
standard treatment for squamous cell carcinoma in situ, 
although it has limitations. Less invasive methods may 
sometimes be preferred. Key words: squamous cell car-
cinoma in situ, Bowen’s disease; cryotherapy; photodyna-
mic therapy; imiquimod; retrospective study.
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Squamous cell carcinoma in situ (carcinoma in situ, 
Bowen’s disease), an intraepidermal malignancy of the 
skin, usually presents as a well-demarcated growing 
erythematous patch or plaque with a scaly or crusted 
surface. Carcinoma in situ lesions can be pigmented or 
verrucous, and are not constantly ulcerated. Clinically 
the lesions may be difficult to distinguish from actinic 
keratosis, superficial basocellular carcinoma (BCC), 
squamous cell carcinoma (SCC), psoriasis, or nummular 
eczema. Histological findings in carcinoma in situ are 
hyperkeratosis and parakeratosis with full-thickness aty-
pia of epidermal keratinocytes; histologically, it does not 
invade through the basement membrane into the dermis. 
No differential diagnosis can be made between carcinoma 
in situ and invasive SCC if the biopsy from the lesion is 
too superficial or does not represent the tumour’s invasive 
part. The risk of progression of any in situ lesion into an 
invasive SCC ranges from 3% to 5% (1). In the Caucasian 
population, carcinoma in situ is very common, with an 
incidence of 14.9–27.8 per 100,000 (2, 3). In Finland, 
carcinoma in situ is not included in the National Cancer 
Registry, and therefore the incidence in our population 
is unknown. Finnish people are Caucasians, the most 
common skin type is Fitzpatrick type III (60%), 30% 
are types I and II and 10% type IV.
In Finland approximately 1,600 new SCCs occur 
annually (4). The major aetiological factors in the 
development of SCC and carcinoma in situ of the skin 
are ultraviolet (UV) radiation and accumulation of UV 
radiation over time. Additional risk factors are fair 
skin, exposure to arsenic, and immunosuppression (5). 
According to the literature, 30–50% of patients with 
carcinoma in situ have a history of non-melanoma skin 
cancer, and 37% have concurrent skin cancers including 
BCC, invasive SCC, or both (6).
The treatment protocols for carcinoma in situ vary. 
Most commonly used are surgical excision, cryotherapy, 
photodynamic therapy (PDT), 5-fluorouracil, and imi-
quimod (7). Surgical excision offers the advantages of 
margin control and confirmation of diagnosis. Only a 
few studies have evaluated the efficacy of surgery for 
carcinoma in situ, and most of these do not mention the 
excision margins (2). In the USA a 4–6-mm margin is 
advised for low-risk SCC, but margins for carcinoma 
in situ are not specified (3). The best option in many 
cases is surgical excision, but less invasive treatment 
options are also needed, because the cutaneous lesions 
may be multiple or occur at sites that are less suitable 
for surgical removal. In elderly patients, in particular, 
co-morbidities may preclude an aggressive treatment 
modality. Few randomized clinical trials elucidate suc-
cess rates of different treatments in carcinoma in situ, 
and most of the studies performed have concentrated 
on comparison of the efficacy of PDT, cryotherapy and 
5-fluoro uracil, and/or imiquimod (8–10). Moreover, the 
follow-up periods in the studies are mostly short, up to 
24 months, but, for PDT, 50 months’ follow-up data are 
also available (1, 11). 
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The present study evaluated the efficacy of different 
treatment modalities used in SCC in situ, including 
surgery. The follow-up period was 8 years. This is a 
clinical study based on routine practice used at our hos-
pital and not on randomization of the patients between 
the different treatment modalities.
MATERIALS AND METHODS
In Finland carcinoma in situ is treated mainly by surgical ex-
cision, cryotherapy or methyl aminolevulinate (MAL)-PDT. 
5-fluorouracil is not used routinely because the drug is only 
available on special permission. Imiquimod is not officially 
approved for treatment of carcinoma in situ, although it is used 
in certain cases. This is a retrospective study of patients with 
carcinoma in situ diagnosed and treated at the Department of 
Dermatology, Skin Cancer Unit, Helsinki University Central 
Hospital, Finland over a period of one year (January to Decem-
ber 2006). All lesions were histologically confirmed. Patients 
whose diagnosis according to biopsy was carcinoma in situ, 
but which, after total excision, was changed into invasive skin 
malignancy (1 carcinoma verrucous, 9 SCC) were excluded. 
Three patients with 5 lesions refused treatment and were also 
excluded from the study. The research team gained approval for 
this retrospective study from the clinical research committee.
The patient’s characteristics that were recorded for the study 
were age, gender of patient, immunosuppressive therapy, ana-
tomical site of lesion, other skin cancers before and at the time 
of biopsy, choice of treatment, recurrence after treatment and 
duration of follow-up. When surgery was carried out, histologi-
cal margins were evaluated. Data were collected by reviewing 
patient medical and histological records and pictures.
Our treatment protocols for carcinoma in situ and the follow-
up are generally standardized. When surgery is used the recom-
mended histological excision margins are minimum 2 mm. Cry-
otherapy is performed after curettage in 2 freeze-thaw cycles 
using liquid nitrogen with 5-mm margins and 1-min margin 
thawing time. In PDT we use MAL. Before cream application 
the lesion is carefully curettaged. After an incubation time of 
at least 3 h the lesion is exposed to red light (630 nm) for 8 
min at a mean light dose of 75 J/cm2. Two PDT treatments are 
given, 7–14 days apart. The response to treatment is controlled 
at least once, 6 months after treatment. Thereafter, follow-up is 
normally arranged by the general practitioner, who re-admits 
the patient to our clinic if recurrence or new lesions appear. 
Possible recurrence was also checked from the patients’ histo-
logical records which are shared by other university hospital 
clinics and general health care centres. 
RESULTS
A total of 263 SCC in situ lesions in 239 patients 
were observed. The mean patient age was 77 years 
(range 35–97 years), 43% (103) were male and 57% 
(136) female. Many of the patients were elderly and 
124 patients died during this almost 8-year follow-up 
period. In all cases the cause of death was unrelated to 
the skin cancer. Eighteen percent (44/239) had immu-
nosuppression, 7% (17) of whom were organ transplant 
recipients. The other reasons for immunosuppressive 
therapy were rheumatoid arthritis (n = 11), systemic 
lupus (n = 1), dermatomyositis (n = 1), polymyositis 
(n = 2), polymyalgia rheumatica (n = 2), idiopathic 
pulmonary fibrosis (n = 1), hepatic disease due to 
cholangitis (n = 1), temporal arteritis (n = 1), psoriasis 
or psoriatic arthritis (n = 5), amyloidosis (n = 1) and 
haemolytic anaemia (n = 1). Four patients had a his-
tory of arsenic exposure and 1 had epidermodysplasia 
verruciformis. 
Most patients had signs of skin damage due to abun-
dant exposure to the sun, and 57% (136) patients had 
previously had one or several premalignant or malignant 
skin cancers; 44% (106) had a history of actinic kera-
tosis, 28% (68) carcinoma in situ, 13% (30) SCC, 36% 
(85) BCC, and 4% (10) malignant melanoma. At the 
time of biopsy 61% (146) had other skin malignancies 
or premalignant lesions. 
In the present material the head and neck were most 
often affected (70%). Males more often had lesions on 
the earlobes (14% vs. 1%) and on the scalp (15% vs. 
1%), whereas females more often had lesions on the 
cheeks (33% vs. 15%). In both males and females the 
trunk (10%), upper (11%) and lower (10%) extremities 
were less frequently affected than the head and neck. 
Surgery was the treatment of choice in the majority 
of lesions (48%) (Fig. 1). Other treatment modalities 
included cryotherapy (24%) and PDT (28%). Surgery 
was used on the trunk (65%) more often than on other 
body sites. If the lesion was located on the lower extre-
mities PDT was most often used (54%). It is also likely 
that larger and more indurated lesions in this area were 
treated with PDT due to contraindications to surgery 
and cryotherapy. The mean duration of follow-up was 
66 months (range 2–93 months). Recurrences appeared 
6–92 months (mean 64 months) after treatment.
The overall recurrence rate was 6.5% . Of all recur-
rences 65% were carcinoma in situ and 35% SCCs 
(Table I). Patients with immunosuppressive treatment 
had only a slightly higher overall recurrence rate than 
immunocompetent patients (11% vs. 6.2%). Twenty-
three patients had actinic keratosis in treated areas, 
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Fig. 1. Treatment modalities (%) in relation to tumour localisation.
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When analysing recurrence rates after different 
treatment modalities, surgical excision had the lowest 
recurrence rate (0.8%). Excision margins varied be-
tween 0 and 5 mm. In 53 cases the margins were less 
than the recommended 2 mm, but there were no recur-
rences in these cases. Only 2 actinic keratoses occurred 
in operated areas, 15 and 51 months after operation. 
When recommended margins were used, there was one 
recurrence of SCC lesion. 
Recurrence rates with the less invasive treatment mo-
dalities were higher; cryotherapy 4.7% (n = 3) and PDT 
18% (n = 13). Following these less invasive methods 11 
carcinomas in situ appeared (1 after cryotherapy and 10 
after PDT) and 5 SCCs (2 after cryotherapy and 3 after 
PDT). All the recurrent carcinomas in situ and SCCs 
were histologically confirmed. There were also 21 actinic 
keratoses in the treated area (12 after cryotherapy and 9 
after PDT). Of recurrent SCCs (6) 5 were excised and 1 
patient died before treatment. Treatments for recurrent 
carcinoma in situ (11) were surgery in 5 cases, imiquimod 
in 3 cases, PDT in 2 cases, and cryotherapy in 1 case.
DISCUSSION
The lack of quality data about surgery and other 
treatments, together with many patient-dependent 
factors, affect therapeutic choice and make it difficult 
to perform a study on gold standard treatment. This is 
the first national retrospective study of SCC in situ in 
Finland, with 239 patients and 263 lesions. 
In present study surgery had the lowest recurrence 
rate (0.8%). There is no clear consensus about the ex-
cision margin for carcinoma in situ. In our clinic the 
recommended histological excision margins are 2 mm, 
although in the study material margins were often less. 
The reason why re-excision was not always carried out 
was mostly patient-dependent, e.g. the patients had co-
morbidities and were hospitalized for other reasons or 
died before re-treatment. However, after surgery with 
less than the recommended margins there were no re-
currences of carcinoma in situ or SCC, only 2 actinic 
keratoses were documented. On the other hand, in one 
case in which excisional margins were much wider than 
recommended (4.5 mm) a SCC appeared. We still sug-
gest 2-mm histological excision margins and, in cases 
in which the margins are too narrow and re-excision 
is not an option, other treatment modalities around the 
scar or careful follow-up should be carried out. 
Recurrence rates with cryotherapy and PDT were 
higher (4.7% and 18%, respectively) than after surgery 
(0.8%). It is possible that there was still underlying 
carcinoma in situ or SCC on the treated area, which 
appeared after superficial treatment and impaired the 
treatment outcome. A biopsy specimen represents only 
a small area of the lesion and does not always exclude 
invasive carcinoma. Ten patients with a diagnosis of 
carcinoma in situ according to biopsy, which was chan-
ged to invasive skin malignancy after total excision, 
were not included in the surgical group.
A randomized placebo-controlled study comparing 
the efficacy of PDT, cryotherapy and 5-fluorouracil 
for treatment of carcinoma in situ found recurrence 
rates of 15%, 21% and 17%, respectively, 12 months 
after the final treatment, while spontaneous healing 
had occurred in 50% of the placebo group (8). In this 
study the diagnosis of recurrence was clinical and 
actinic keratoses were also regarded as recurrences. 
In our study the recurrence rate with actinic keratosis 
following cryotherapy was similar, but much higher 
following PDT (30% vs. 15%). This may be due to our 
longer follow-up time and the selection of larger lesions 
in the PDT group because our study was not randomi-
zed. Our study is not comparable to randomized PDT 
studies because it is a retrospective study and treatment 
regimens will modify treatment results.
We could confirm previous observations that 
carci noma in situ lesions are typically located on 
sun-exposed areas. In our material 57% of patients 
had previously had a premalignant or malignant skin 
cancer, which is higher than the published proportion 
of 30–50% (10). At the time of biopsy 61% of patients 
had other malignant or premalignant lesions. We did 
not report actinic keratosis as recurrence of carcinoma 
in situ. Most of our patients had sun-damaged skin with 
numerous premalignant lesions and field cancerization, 
and it was highly probable that new actinic keratoses 
would appear during the 8-year follow-up. Carcinoma 
in situ and SCC are more likely to be true recurrences 
after treatment of carcinoma in situ.
Retrospective studies have limitations because the 
choice of treatment is influenced by several factors. 
At present, no treatment modality is clearly superior, 
and the choice of treatment depends on location, size, 
thickness, and number of lesions; thick and small le-
sions are more often treated by surgery or cryotherapy 
and large thinner ones, especially on the face or lower 
limbs, by PDT. In addition, the patient’s characteristics, 
clinician’s expertise, availability of therapy, and the 
institutional experience are important in selection of 
the therapeutic approach (11). All thick and chronically 
ulcerative carcinomas in situ should be operated, be-
cause of the possibility of underlying SCC. Although 
surgery is the first-line treatment for carcinoma in 
situ, less invasive treatment modalities are needed for 
Table I. Recurrences after different treatment modalities





Excision 1/125 (0.8) 1
Cryotherapy 3/64 (4.7) 1 2
Photodynamic therapy 13 /74 (18) 10 3
Total, n/total (%) 17/263 (6.5) 11/263 (4.2) 6/263 (2.3)
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multiple, very large carcinomas in situ or those located 
at sites that heal poorly after operation. In some cases 
combination treat ment could be helpful, especially for 
large carcinomas in situ, e.g. operating first on deeper 
lesions and then treating the residual area with PDT. In 
addition, in some cases the cosmetic result after PDT 
is better than after surgery (8, 12). In elderly patients 
co-morbidities may preclude an aggressive treatment 
modality. Thus the advantages and disadvantages of 
each treatment method should be considered on an 
individual case basis. 
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